Previous 10 | Next 10 |
2023-12-07 07:16:38 ET More on Wave Life Sciences Wave Life Sciences Ltd. (WVE) Q3 2023 Earnings Call Transcript Wave Life Sciences: Excellent Early Data, Major Collaborations, Needs Cash Wave Life Sciences proposes public offering of ordinary shares and pre-funded w...
2023-12-06 16:18:00 ET More on Wave Life Sciences Wave Life Sciences Ltd. (WVE) Q3 2023 Earnings Call Transcript Wave Life Sciences: Excellent Early Data, Major Collaborations, Needs Cash Wave Life Sciences GAAP EPS of $0.07 beats by $0.25, revenue of $49.2M beats by...
CAMBRIDGE, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that it has commenced an underwritten public offering of $10...
WVE-006 is uniquely designed to correct the disease-causing RNA mutation in AATD, thereby restoring circulation of wild-type M-AAT protein and reducing Z-AAT protein levels to address both lung and liver manifestations of the disease Wave earned $20 million USD milestone from GSK for in...
2023-11-29 15:00:01 ET Summary Biogen's latest Alzheimer's drug, Aduhelm, faced challenges after FDA approval, leading to concerns about efficacy and high costs. Biogen and Eisai's latest FDA-approved lecanemab faces similar risks; as a result, shares are down over 20% year-over-y...
CAMBRIDGE, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Offi...
2023-11-10 12:04:06 ET Wave Life Sciences Ltd. (WVE) Q3 2023 Earnings Conference Call November 09, 2023 08:30 AM ET Company Participants Kate Rausch - Vice President, Investor Relations & Corporate Affairs Paul Bolno - President & Chief Executive Officer ...
2023-11-09 07:33:57 ET More on Wave Life Sciences Wave Life Sciences: Excellent Early Data, Major Collaborations, Needs Cash Wave Life Sciences Q3 2023 Earnings Preview Wave Life Sciences spikes on R&D Day Seeking Alpha’s Quant Rating on Wave Life ...
Initiated RestorAATion clinical program for WVE-006, industry’s first-ever RNA editing clinical candidate, following approval of CTAs; dosing on track for 4Q 2023 and first-in-human proof-of-mechanism data anticipated in 2024 On track to deliver dystrophin data from p...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
News, Short Squeeze, Breakout and More Instantly...
Wave Life Sciences Ltd. Company Name:
WVE Stock Symbol:
NASDAQ Market:
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unloc...
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is...
2024-05-15 07:00:05 ET Tiago Fauth from Wells Fargo issued a price target of $11.00 for WVE on 2024-05-15 05:53:00. The adjusted price target was set to $11.00. At the time of the announcement, WVE was trading at $5.84. WVE currently trades -24.58% versus its 52 week hig...